Home›Research›Compare›Ac-SDKP vs Larazotide
Peptide ComparisonAc-SDKP vs Larazotide
Both are Tissue Repair peptides.
Ac-SDKP
N-acetyl-seryl-aspartyl-lysyl-proline
No providers listed yet
Larazotide
AT1001
Half-life: ~30 minutes (local gut action)
11 providers listed
Larazotide carries stronger published evidence (RCT, 3 key studies) than Ac-SDKP (Cohort study, 4); both are research compounds.
Ac-SDKP
Evidence
Half-life
—
Larazotide
Evidence
Half-life
~30 minutes (local gut action)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Larazotide |
| Further along in FDA review | Larazotide |
| Oral administration option | Larazotide |
| More provider options (0 vs 11) | Larazotide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Ac-SDKP
Larazotide
Ac-SDKP
Device surface-functionalized ac-SDKP nanoassemblies accelerate endothelial recovery through dual anti-inflam…
Ac-SDKP Attenuates Silica-Induced Pulmonary Fibrosis by Inhibiting ALKBH1-Mediated m(6)A Demethylation of miR…
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythe…
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Larazotide
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized control…
Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stre…
A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during glu…
About Ac-SDKP
Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.
About Larazotide
Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Ac-SDKP
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Larazotide
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Where to source these peptides
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.